Corporate | 7 April 2006 10:11

STRATEC increases distribution to shareholders by 50%

Corporate-news transmitted by DGAP – a company of EquityStory AG. The issuer is solely responsible for the content of this announcement. —————————————————————————— STRATEC increases distribution to shareholders by 50% Birkenfeld, April 7, 2006 The Supervisory and Management Boards of STRATEC Biomedical Systems AG, which is listed in the Prime Standard, decided at their meeting on April 6, 2006 to propose to the Annual General Meeting held on June 23, 2006 that a dividend of Euro 0.30 per share be distributed to shareholders for the 2005 financial year (previous year: dividend of Euro 0.15, plus a bonus of Euro 0.05). Subject to the consent of the Annual General Meeting, the company would then have increased its distribution by 50% compared with the previous year, which is equivalent to the development of consolidated earnings. The increase in the distribution proposed by the Supervisory and Management Boards is intended to enable shareholders to participate in the superb earnings performance of the STRATEC Group in the 2005 financial year. The Management Board will be presenting the consolidated financial statements for 2005 within the framework of its Annual Results Telephone Conference on April 27, 2006 (conference language: German). Press representatives, investors and analysts who would like to take part in this telephone conference are requested to register for this purpose with our Investor Relations Team, Tel: +49 (0)7082 7916-190. About STRATEC STRATEC Biomedical Systems AG (http://www.stratec-biomedical.de) designs and manufactures fully automated systems for its partners in the fields of clinical diagnostics and biotechnology. These partners market such systems, in general together with their own reagents, to laboratories and research institutes around the world. The company develops its products on the basis of its own patented technologies. Shares in the company (SIN: 728900 / ISIN: DE0007289001) are traded in the Prime Standard segment of the Frankfurt Stock Exchange, in the Gate-M trading segment of the Stuttgart Stock Exchange and on other exchanges. The STRATEC Group comprises the listed holding company ‘STRATEC Biomedical Systems AG’, as well as the subsidiaries ‘STRATEC NewGen’, ‘Robion AG’ and ‘Sanguin’. Further information can be obtained from: STRATEC Biomedical Systems AG André Loy, Investor Relations Gewerbestrasse 37, 75217 Birkenfeld Germany Tel: +49 7082 7916-190 Fax: +49 7082 7916-999 E-Mail: ir@stratec-biomedical.de (c)DGAP 07.04.2006 ————————————————————————— language: English emitter: STRATEC Biomedical Systems AG Gewerbestraße 37 75217 Birkenfeld Deutschland phone: +49 (0)7082 7916 0 fax: +49 (0)7082 7916 999 email: info@stratec-biomedical.de WWW: www.stratec-biomedical.de ISIN: DE0007289001 WKN: 728900 indexes: stockmarkets: Geregelter Markt in Frankfurt (Prime Standard), Stuttgart; Freiverkehr in Berlin-Bremen, München, Hamburg, Düsseldorf End of News DGAP News-Service —————————————————————————